

**Supplemental Table 3. Resistance among *A. baumannii* by sp**

	Inpatient ward		IC
Amikacin	3,882	31.54%	4,010
Tobramycin	5,541	39.10%	4,873
Aminoglycoside	4,072	29.64%	4,056
Doxycycline	21	33.33%	55
Minocycline	338	44.07%	638
Tetracyclines	355	43.61%	685
Doripenem	9	100.00%	11
Imipenem	4,799	34.77%	4,448
Meropenem	3,296	43.75%	3
Carbapenem	5,173	33.90%	4,879
Ampicillin/Sulbactam	4,481	40.06%	3,975
Colistin	46	4.93%	49
Polymyxin B	42	7.32%	52
Polymyxin	78	5.64%	99
Trimethoprim/Sulfamethoxazole	7,715	56.33%	6,542
MDR*	4,706	29.15%	4,233
Carbapenem + Aminoglycoside	2,573	17.97%	2,548
Aminoglycoside + Amp/Sulbactam	2,065	19.07%	1,953
Aminoglycoside + Minocycline	221	30.23%	400
Carbapenem + Amp/Sulbactam	2,615	24.36%	2,457

\*MDR = multidrug resistant, defined as non-susceptible to  $\geq 1$  drug in  $\geq 3$  classes

**ecimen location**

U	NH		Outpatient		Ott
35.30%	353	40.34%	1,629	30.32%	105
38.46%	553	61.93%	2,387	37.89%	111
29.64%	343	36.33%	1,749	26.28%	85
51.40%	NR		9	12.33%	
46.64%	8	57.14%	289	43.66%	0
47.54%	8	57.14%	298	40.99%	0
100.00%			8	72.73%	
35.19%	423	47.64%	1,777	30.15%	92
47.26%	210	50.60%	1,132	34.14%	85
34.90%	441	47.12%	1,901	28.00%	103
42.46%	328	46.46%	1,709	34.76%	104
5.42%	1	5.56%	15	6.64%	1
12.12%			37	16.89%	
7.65%	1	5.56%	50	11.93%	1
55.44%	682	75.69%	3,147	49.59%	185
28.74%	450	46.54%	1,885	26.23%	121
19.28%	193	20.93%	974	15.13%	60
21.76%	159	22.98%	849	18.23%	45
29.78%	7	53.85%	162	25.71%	0
27.02%	202	28.94%	895	18.78%	48

ner
42.33%
37.88%
29.01%
0.00%
0.00%
32.74%
63.91%
35.27%
45.22%
20.00%
20.00%
64.01%
41.30%
20.69%
19.65%
0.00%
21.24%

**Supplemental Table 4. CLSI minimum inhibitory concentration (**

Antibiotic	2003		2007	
	Susceptible	Resistant	Susceptible	Resistant
Gentamicin	$\leq 4$	$\geq 8$	$\leq 4$	$\geq 8$
Trimethoprim/sulfa	$\leq 2/38$	$\geq 8/152$	$\leq 2/38$	$\geq 8/152$
Amikacin	$\leq 16$	$\geq 32$	$\leq 16$	$\geq 32$
Tobramycin	$\leq 4$	$\geq 8$	$\leq 4$	$\geq 8$
Polymyxin B	None	None	None	None
Colistin	None	None	None	None

**MCI) breakpoints, 2003, 2007, 2012**

2012	
Susceptible	Resistant
$\leq 4$	$\geq 16$
$\leq 2/38$	$\geq 4/76$
$\leq 16$	$\geq 64$
$\leq 4$	$\geq 16$
$\leq 2$	$\geq 4$
$\leq 2$	$\geq 4$